AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
Tern Plc has appointed Jane Karwoski (also known as Jane McCracken) and Iain Ross as independent Non-Executive Directors.
Sarah Payne and Alan Howarth have stepped down from the Board to focus on other business interests.
The current Board comprises Ian Ritchie (Non-Executive Chairman), Jane McCracken, and Iain Ross.
Tern Plc (LSE:TERN), an investment company dedicated to supporting high-growth, early-stage disruptive Internet of Things (IoT) technology businesses, has announced significant changes to its Board of Directors. The company has welcomed Jane Karwoski, known as Jane McCracken, and Iain Ross as independent Non-Executive Directors, effective immediately. This development follows the departure of Sarah Payne and Alan Howarth, who have stepped down to concentrate on their other business ventures.
Following these changes, the Board now consists of Ian Ritchie serving as Non-Executive Chairman, along with new appointees Jane McCracken and Iain Ross. Jane McCracken brings extensive experience from her career in high-growth technology sectors across the USA, UK, and Europe. Her background includes roles as an entrepreneur, investor, board member, and advisor in areas such as software, e-commerce, digital health, and clinical research. Most recently, she held the position of Entrepreneur-in-Residence at the Advanced Technology Development Center at Georgia Institute of Technology. Additionally, she serves as the Chief Growth Officer for Corps Team, a US-based search and staffing firm, and holds board positions with Edinburgh Worldwide Investment Trust plc and Radyus Research.
Iain Ross contributes over 40 years of experience in the international life sciences and technology sectors. His career encompasses significant roles in multinational pharmaceutical and biotech companies, where he has completed various financing transactions and has extensive cross-border management experience. Ross has participated in eight initial public offerings (IPOs) and has been involved in mergers and acquisitions across Europe, the USA, and the Pacific Rim. Currently, he serves as Chairman of NASDAQ-listed Silence Therapeutics plc and Executive Chairman of ReNeuron Group plc, in addition to holding other non-executive director roles.
Ian Ritchie, Chairman of Tern, expressed enthusiasm for the new appointments, stating that the skills and experience of McCracken and Ross will be invaluable in generating returns for shareholders. He also acknowledged the significant contributions of the departing board members and wished them well in their future endeavors.
